Edgar Filing: IDEXX LABORATORIES INC /DE

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â TWIGGE GIOVANI

2. Date of Event Requiring Statement (Month/Day/Year)
12/30/2016

3. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [IDXX]

(Last)

(First)

(Middle)

IDEXX LABORATORIES, INC.,Â ONE IDEXX DRIVE

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
CVP - Chief HR Officer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

WESTBROOK,Â MEÂ 04092

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	17,729	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Unit	Â ⁽¹⁾	Â ⁽¹⁾	Common Stock	5,512 ⁽¹⁾	$ ⁽¹⁾	D	Â
Non-Qualified Stock Option (right-to-buy)	Â ⁽²⁾	02/13/2019	Common Stock	11,372 ⁽¹²⁾	$ 43.71 ⁽¹²⁾	D	Â
Incentive Stock Option (right-to-buy)	Â ⁽³⁾	02/13/2019	Common Stock	2,286 ⁽¹²⁾	$ 43.71 ⁽¹²⁾	D	Â
Non-Qualified Stock Option (right-to-buy)	Â ⁽⁴⁾	02/13/2023	Common Stock	14,750 ⁽¹²⁾	$ 45.84 ⁽¹²⁾	D	Â
Incentive Stock Option (right-to-buy)	Â ⁽⁵⁾	02/13/2023	Common Stock	2,180 ⁽¹²⁾	$ 45.84 ⁽¹²⁾	D	Â
Non-Qualified Stock Option (right-to-buy)	Â ⁽⁶⁾	02/13/2024	Common Stock	12,814 ⁽¹²⁾	$ 62 ⁽¹²⁾	D	Â
Incentive Stock Option (right-to-buy)	Â ⁽⁷⁾	02/13/2024	Common Stock	1,612 ⁽¹²⁾	$ 62 ⁽¹²⁾	D	Â
Non-Qualified Stock Option (right-to-buy)	Â ⁽⁸⁾	02/13/2025	Common Stock	19,354 ⁽¹²⁾	$ 79.54 ⁽¹²⁾	D	Â
Incentive Stock Option (right-to-buy)	Â ⁽⁹⁾	02/13/2025	Common Stock	1,256 ⁽¹²⁾	$ 79.54 ⁽¹²⁾	D	Â
Non-Qualified Stock Option (right-to-buy)	Â ⁽¹⁰⁾	02/13/2026	Common Stock	22,028	$ 67.85	D	Â
Incentive Stock Option (right-to-buy)	Â ⁽¹¹⁾	02/13/2026	Common Stock	1,476	$ 67.85	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
TWIGGE GIOVANI IDEXX LABORATORIES, INC. ONE IDEXX DRIVE WESTBROOK,Â MEÂ 04092	Â	Â	Â CVP - Chief HR Officer	Â

Signatures

/s/ Giovani Twigge		01/06/2017
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").
(2)	Grant of option to buy 7,394 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2013, without giving effect to the Stock Split.
(3)	Grant of option to buy 1,143 shares of Issuer common stock that vests in one installment on February 14, 2017, without giving effect to the Stock Split.
(4)	Grant of option to buy 7,375 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2014, without giving effect to the Stock Split.
(5)	Grant of option to buy 1,090 shares of Issuer common stock that vests in one installment on February 14, 2018, without giving effect to the Stock Split.
(6)	Grant of option to buy 6,407 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2015, without giving effect to the Stock Split.
(7)	Grant of option to buy 806 shares of Issuer common stock that vests in one installment on February 14, 2019, without giving effect to the Stock Split.
(8)	Grant of option to buy 9,677 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split.
(9)	Grant of option to buy 628 shares of Issuer common stock that vests in one installment on February 14, 2020, without giving effect to the Stock Split.
(10)	Grant of option to buy22,028 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2017.
(11)	Grant of option to buy 1,476 shares of Issuer common stock that vests as to 1 share on February 14, 2017, February 14, 2018 and February 14, 2020, respectively, and as to the remainder on February 14, 2021.
(12)	The number of remaining derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.